三种佐剂减量灭活脊髓灰质炎疫苗(IPV-Al SSI)与全剂量IPV Vaccine SSI在曾于3、5、12月龄和5岁接种IPV的青少年中加强接种的首次人体安全性和免疫原性研究
240名10-15岁丹麦青少年按1/3、1/5、1/10 IPV-Al或全剂量IPV Vaccine SSI加强接种,三种减量疫苗均具高免疫原性但加强效应低于全剂量疫苗;未发生严重不良事件或重度不良事件,59.2%受试者报告至少1起不良事件,多为轻度。
要点
- 三种减量IPV-Al加强后均具高免疫原性,但加强效应低于全剂量IPV Vaccine SSI。
- 未发生严重不良事件和重度不良事件,多数不良事件为轻度。
- 注射部位疼痛最常见,各组发生率24.6%至43.3%。
核心结论
- 三种减量IPV-Al SSI在青少年中安全,加强效应令人满意。
研究设计与样本
- 240名10-15岁丹麦青少年,儿童期已接种IPV,加强接种1/3 IPV-Al、1/5 IPV-Al、1/10 IPV-Al或IPV Vaccine SSI。
- 将三种IPV-Al SSI的加强效应(GMTR)与IPV Vaccine SSI比较并评价非劣效性。
主要发现
- 接种前GMT在各组间相近:1型926、2型969、3型846(总试验人群)。
- 1型GMTR:1/3 IPV-Al为17.0、1/5 IPV-Al为13.0、1/10 IPV-Al为7.1、IPV Vaccine SSI为42.2。
- 2型GMTR:1/3 IPV-Al为12.5、1/5 IPV-Al为13.1、1/10 IPV-Al为7.6、IPV Vaccine SSI为47.8。
- 3型GMTR:1/3 IPV-Al为14.5、1/5 IPV-Al为16.2、1/10 IPV-Al为8.9、IPV Vaccine SSI为62.4。
- 三种IPV-Al配方均具高免疫原性,但在此加强接种试验中低于IPV Vaccine SSI。
关键数值与推荐
- 未发生严重不良事件(SAE),未发生重度不良事件。
- 59.2%的受试者报告至少1起不良事件。
- 注射部位疼痛为各组最常见不良事件,发生率24.6%至43.3%。
- 注射部位发红和肿胀在多数组<5%,所有组<10%。
- 最常见全身不良事件为疲乏(8.2%至15.0%)和头痛(15.0%至28.3%),多数不良事件为轻度。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: There is a demand of affordable IPV in the World. Statens Serum Institut (SSI) has developed three reduced dose IPV formulations adsorbed to aluminium hydroxide; 1/3 IPV-Al, 1/5 IPV-Al and 1/10 IPV-Al SSI, and now report the results of the first investigations in humans. METHODS: 240 Danish adolescents, aged 10-15years, and childhood vaccinated with IPV were booster vaccinated with 1/3 IPV-Al, 1/5 IPV-Al, 1/10 IPV-Al or IPV Vaccine SSI. The booster effects (GMTRs) of the three IPV-Al SSI were compared to IPV Vaccine SSI, and evaluated for non-inferiority. IMMUNOGENICITY RESULTS: The pre-vaccination GMTs were similar across the groups; 926 (type 1), 969 (type 2) and 846 (type 3) in the total trial population. The GMTRs by poliovirus type and IPV formulation were: Type 1: 17.0 (1/3 IPV-Al), 13.0 (1/5 IPV-Al), 7.1 (1/10 IPV-Al) and 42.2 (IPV Vaccine SSI). Type 2: 12.5 (1/3 IPV-Al), 13.1 (1/5 IPV-Al), 7.6 (1/10 IPV-Al) and 47.8 (IPV Vaccine SSI). Type 3: 14.5 (1/3 IPV-Al), 16.2 (1/5 IPV-Al), 8.9 (1/10 IPV-Al) and 62.4 (IPV Vaccine SSI) Thus, the three IPV-Al formulations were highly immunogenic, but inferior to IPV Vaccine SSI, in this booster vaccination trial. SAFETY RESULTS: No SAE and no AE of severe intensity occurred. 59.2% of the subjects reported at least one AE. Injection site pain was the most frequent AE in all groups; from 24.6% to 43.3%. Injection site redness and swelling frequencies were<5% in most and<10% in all groups. The most frequent systemic AEs were fatigue (from 8.2% to 15.0%) and headache (from 15.0% to 28.3%). Most AEs were of mild intensity. In conclusion, the three IPV-Al SSI were safe in adolescents and the booster effects were satisfactory. ClinicalTrials.gov registration number: NCT02280447.
引用
- Lindgren LM, Tingskov PN, Justesen AH, et al. First-in-human safety and immunogenicity investigations of three adjuvanted reduced dose inactivated poliovirus vaccines (IPV-Al SSI) compared to full dose IPV Vaccine SSI when given as a booster vaccination to adolescents with a history of IPV vaccination at 3, 5, 12months and 5years of age. Vaccine. 2016. PMID: 28027810. doi:10.1016/j.vaccine.2016.12.027
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。